Clinical Trial Update: Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating Paroxetine-CR for post-traumatic stress disorder that remains symptomatic after exposure therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Paroxetine-CR (paroxetine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Stress Disorders, Post-Traumatic | Phase 1, Phase 2 | Status: COMPLETED